anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention comprises racemates and optically active isomers of ethers of 2-piperidylphenylmethanols (form B) of the general formula &lt;FORM:0842671/IV(b)/1&gt; and acid addition salts thereof wherein R represents a C1-4 alkyl or alkenyl group and Ar represents an unsubstituted phenyl group, or a phenyl group substituted by alkoxy or methylenedioxy and the preparation thereof by etherifying an appropriate 2-piperidylphenylmethanol (form B) or an acid addition salt thereof, the nitrogen atom of the 2-piperidylphenylmethanol being optionally protected during the reaction by a benzyl or acyl (including formyl) group which is subsequently removed, or by condensing a compound of the general formula:  &lt;FORM:0842671/IV(b)/2&gt; with an alcohol, ROH or an alkali metal derivative thereof.  The compounds of the invention may also be prepared by reducing a compound of the general formula &lt;FORM:0842671/IV(b)/3&gt; preferably by hydrogen in the presence of a hydrogenation catalyst.  The racemic ethers may be separated into the individual isomers by direct solution.  1-Phenyl-1-(1-benzyl-2-piperidyl) methamol is prepared by treating 1-phenyl-1-(2-piperidyl) methanol (form B) with benzyl chloride. Laevo-1 - phenyl - 1 - (1 - benzoyl - 2 - piperidyl) methanol is prepared from laevo-1-phenyl-1-(2-piperidyl) methanol and benzoyl chloride.  1-(3:4 Methylenedioxy) - and 1 - p - ethoxyphenyl - 1 - (2 - piperidyl) chloro methanes are prepared by the action of thionyl chloride on the corresponding alcohols, obtained by reduction of the corresponding benzoyl pyridines.ALSO:Pharmaceutical preparations comprise compounds of the general formula &lt;FORM:0842671/VI/1&gt; (in form B) and acid addition salts thereof when Ar is an unsubstituted phenyl or an alkoxy or methylenedioxy phenyl radical and R is a C1-4 alkyl or alkenyl group in association with a pharmaceutical carrier.  Preparations may comprise solutions, suspensions, syrups, elixirs, emulsions, powders, tablets or capsules for oral ingestion or sterile solutions or suspensions in water or other liquids, with or without the addition of soluble or insoluble diluents and/or solid or liquid excipients for parenteral administration.  Preparations contain at least 0,01% by weight of active substance for oral preparations and at least 0,02% by weight of such substance for injectable solutions. Suitable salts are the hydrochlorides, phosphates, nitrates, sulphates, maleates, fumerates, citrates, tartrates, methanesulphonates and ethanedisulphonates.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a molded body for dental purpose and a resin material for dental purpose that have excellent safety without anxiety of elution of bisphenol-A and satisfy the physical properties that are required in denture base, tentatively covered dental crown, artificial teeth or the like.  &lt;P&gt;SOLUTION: The molded body for dental purpose according to this invention is mainly composed of a copolymerized polyester resin (PET-G) including the polyethylene terephthalate (PET) units and the poly-1,4-dimethylenecyclohexane terephthalate (PCT) units and of polyethylene naphthalate (PEN) at a weight ratio of (20 to 90)/(80 to 10). The resin material for dental purpose according to this invention has excellent heat resistance to be used even at 100°C. Further, it has 1.5 fold flexural strength that of PET-G. It can be colored to desired color as a denture base without damage to transparency and shows good adhesion to acrylic resin, too. Fibrous reinforcing agent and other polyester resin also may be admixed to this resin material.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To make possible the diagnosis of various cancers by using a monoclonal antibody which reacts specifically with the cancer cells of the human gland as a reagent useful for measuring the corresponding antigen in the bodily fluid by immonoassay. CONSTITUTION:The monoclonal antibody which reacts specifically with the cancer cells of the human gland is formed from the hybridoma obtd. by the confluence of the immune cells of the mammal immunized by the cancer cells of the human lung gland and myeloma cells. This method for prepn. consists first in the prepn. of the hybridoma from the body by the conventional method. Mouse, etc. are generally used for the mammal to immunize the cancer cells of the human lung gland. The antibody generative cells are then made confluent with the myeloma cells. The hybridoma obtd. in the above-mentioned manner is cultured in an ordinary hybridoma selecting medium and the necessary hybridoma is separated. The diagnosis of various cancers is made possible by measuring the corresponding specific amtingens in the patient&#39;s blood by an immunological method using the monoclonal antibody.
The present invention discloses a novel ethoxy combretastatin (Combretastatin) and the whole synthesis process of the former drug. The 4&#39; location of the combretastatin B aromatic ring is chemically modified by ethoxy. At the same time, the 3&#39; location hydroxide of the combretastatin B aromatic ring is changed into phosphate  or water-solution former drug of phosphorylcholine in-type salinity. The 3&#39; location amido combretastatin experiences chemical modification of the 4&#39; location ethoxy. Fatherly, amino acid side chain is introduced to the amido to get amino acid amide water-solution former drug. The structure is shown in (1). ethoxy combretastatin is of strong inhibition in the concentration of canaliculus albumen, and can be used in the anti-tumor treatment and anti-angiogenesis therapy.
The invention provides an intelligent closestool with a health detection function, which comprises the following components: the toilet comprises a toilet body, an upper cover, a seat ring, a water tank component and a health detection system. Wherein the health detection system comprises: the system comprises a control center, a physical sign information input storage module, an identity recognition module, an excrement detection module and a communication module, wherein the physical sign information input storage module, the identity recognition module, the excrement detection module and the communication module are electrically connected with the control center. The physical sign information input storage module is used for inputting and storing the weight information of a plurality of users. The excrement detection module is used for detecting an excrement sample of a current user and sending detection information to the control center. The control center is used for analyzing the detection information to obtain the health information of the current user, and sending the health information of the current user to the communication equipment of the current user through the communication module. This intelligent closestool with health detection function can monitor user&#39;s health status to intelligent closestool&#39;s function has been strengthened, user experience has been improved.
PURPOSE: To obtain the subject preparation not lowering thrombin activity when used jointly with an antacid and excellent in stability. CONSTITUTION: This preparation does not cause lowering of thrombin when jointly used with an antacid (e.g. aluminunu silicate or magnesium carbonate). Preferably, the preparation does not contain the antacid. Thrombin derived from human is preferably blended with 50-500mg, 10-100mg arginine and 10-100mg citric acid based on 500-10000 &#39;unit of thrombin derived from human as dried preparation in the preparation. Furthermore, the preparation is preferably used in a form of a kit from the viewpoint of keeping thrombin activity and as the kit and the kit includes e.g. a kit composed of a solid like thrombin preparation for kit not containing the antacid and a liquid antacid which are each put in a different container.  When the preparation is used in a kit form, the antacid is administered and then, the thrombin preparation is administered or both of them are simultaneously preferably administered.
The invention relates to a sweet-potato grape wine and a preparation method thereof. Sweet potatoes and grapes are used as the main raw materials, and cooked glutinous rice and barley malt are used as auxiliary materials. Firstly, the cooked glutinous rice and the barley malt are prepared into malt syrup, the sweet potatoes are cooked and smashed, and the barley malt and yeast (distiller&#39;s yeast) are added into the sweet potatoes to perform fermentation. Fermentation liquid is settled and filtered and the auxiliary materials are dipped in the liquid for 2 days, and then a sauce-flavor sweet-potato grape wine having an alcohol content of 38-55% (v/v) and a sweet-potato grape wine having an alcohol content of 12-28% (v/v) can be obtained through distillation. The produced sweet-potato grape wine has advantages of mellow smell, good taste, and the like, has obvious preventing and treating functions for hyperlipidemia, hypertension, hyperglycemia, cholesterol and obesity, and has functions of promoting metabolism of human bodies and boosting immunity for common people. The drinking amount is determined according to the personal interests, and frequent drinking of the wine is beneficial for health.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a fermentation-treated material of Hemerocallis fulva var. sempervirens exhibiting better sleep improving actions or an ACE (angiotensin I converting enzyme) inhibitory activity than those of ingestion of the plant of the Hemerocallis fulva var. sempervirens itself and a food material and a food containing the fermented plant in order to effectively utilize the Hemerocallis fulva var. sempervirens.  &lt;P&gt;SOLUTION: The fermentation-treated material exhibits sleep improving effects as compared with those of the plant Hemerocallis fulva var. sempervirens by a fermentation treatment of the Hemerocallis fulva var. sempervirens and improves taste. The lactic acid fermentation-treated material exhibiting the ACE inhibitory activity effects can be obtained. Furthermore, the food material and food having great utilization value with enhanced actions can be obtained.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
NEW MATERIAL:A compound of formula I [X and Y are each RCO- [R is &gt;=5C alkyl or (substituted)aryl], RSO2- [R is lower alkyl or (substituted)aryl] or H, however, being not H at the same time] or its salt. EXAMPLE:11-O-capryl SF2587 material. USE:An antibiotic with antitumor activity, which is useful as a carcinostatic agent. PREPARATION:A SF2587 material of formula II is reacted with an acylating agent (e.g. capryl chloride) or sulfonylating agent (e.g. methanesulfonyl chloride) in the presence of a base (e.g. dimethylaminopyridine) at -10-100 deg.C to obtain the objective compound of the formula I. The compound of the formula II can be obtained by separation from a liquid extract for cultured bacteria from Actinomycetes SF2587 strain (FERM P-9831) classified as Streptomyces sp.
PURPOSE:A liver-spot improver, containing the terrestrial part of leaves or stems of honewort or parsley as an essential component, produced from a very highly safe vegetable used as food for a long time as a raw material and useful for food, cosmetic, etc. CONSTITUTION:A liver-spot improver containing an extract, obtained by extracting dried powder of the terrestrial part of annual or biennial herb umbelliferous honewort and/or parsley which are edible plants or a readily metabolizable extract obtained by extracting the terrestrial part with an aqueous solvent, e.g. water, physiological saline or dilute aqueous organic acid, which is a solvent containing at least &gt;=95wt% water as an essential component. The above-mentioned improver is formulated into a food form, e.g. tea, refreshing drink, pill, powder, confectionery, bread, cookie or curry, etc., as an internal improving method or into a cosmetic, e.g. toilet water, pack, face washing water or soap, etc. The above-mentioned essential component may be eaten in 500-10,000mg/adult/day expressed in terms of dry raw material. EFFECT:The peroxylipid value of user&#39;s epidermis on trial is being normalized and this improver is considered as useful for cosmetic dermatitis, pimples, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for more effective treatment of cancer with less harmful adverse reaction.  &lt;P&gt;SOLUTION: The method relates to a treatment of cancer for a patient requiring treatment of cancer. The method includes administration of a first amount of histone deacetylase inhibitor in a first treatment process and a second amount of histone deacetylase inhibitor in a second treatment process. The first amount and the second amount together contain therapeutically effective amounts. A combination of HDAC (histone deacetylase) inhibitors and a radiation therapy is synergistically effective. In one embodiment, the combination therapeutic method relates to the treatment of cancer.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain an X-ray contrast composition for digestive tracts, having high safety, easily swallowable and giving a clear X-ray image in contrast with conventional contrast agent composed of barium or iodine compound. CONSTITUTION:The contrast composition for digestive tracts for radiography is composed of a component containing nonmetallic elements having atomic number of &lt;=8 (e.g. H, C, O and N) as main constituent elements. The composition is preferably produced by compounding 1-99% carbohydrates and 99-1% proteins in such a manner as to get a composition having a lipid content of &lt;=0.5% and a density of 1.10-1.30g/cm&lt;3&gt;. The carbohydrate and the protein may be pure substances or a food rich in those substances, e.g. a food rich in carbohydrate (e.g. honey, starch syrup, reduced oligosaccharide, starch, sweet potato, potato and fruit) or a food rich in protein (e.g. kwalk, fresh cheese, various cheeses, defatted milk and concentrated whey protein).
PROBLEM TO BE SOLVED: To obtain a cosmetic material having excellent whitening action and capable of giving tension and luster to the skin by allowing to contain refined SAKE and a koji acid. SOLUTION: This cosmetic material contains 0.1-95wt.% refined SAKE and 0.001-5wt.% koji acid expressed by the formula (R&lt;1&gt; and R&lt;2&gt; are each H, a 3-22C acyl or alkyl) or its derivative. As the refined SAKE, pure rice refined SAKE and specifically fermented SAKE using rice with high milling rate which are rich in vitamins, amino acids, organic acids, etc., and as the koji acid derivative, koji acid monobutylate, etc. can be cited. The whitening action of the koji acid and moisture retaining and skin beautifying effects of the refined SAKE are synergistically reinforced to express the effects by using the refined SAKE with the koji acid.  A water-based component, powder, a surfactant, an oil solution, a moisture retaining agent, an alcohol, a pH adjuster, an antiseptic agent, a pigment, an antioxidant, a UV absorber, a thickener, an essence, a skin beautifying agent, etc. can be properly blended to prepare an emulsion solution, a cream, a cosmetic solution, a pack, etc.
PURPOSE:To prepare a medicinal compd. which effectively prevents the growth of a human immunodeficiency virus without showing side effect by reacting a specific sulfonamide deriv. of beta-cyclodextrin with a sulfonating agent. CONSTITUTION:A sulfonamide deriv. of beta-cyclodextrin wherein at least one of the seven D-glucose units constituting beta-cyclodextrin has been substd. by a unit of the formula is reacted with a sulfonating agent, and if necessary the reaction product is converted into a salt, giving a polysulfuric ester of the sulfonamide deriv. or a salt of the ester. In the formula, R&lt;1&gt; is alkyl, phenyl, naphthyl, or heterocyclic. The sulfonamide deriv. is a new compd. and prepd. by reacting beta-cyclodextrin with a substd. sulfonic acid halide, separating and purifying the reaction product if necessary, reacting it with ammonia, and sulfonamidating the resulting product by a suitable method.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an IL-18 binding protein, especially an antibody binding to human interleukin-18 (hIL-18).  &lt;P&gt;SOLUTION: There is provided an antibody which is a perfect human antibody. A preferable antibody has high affinity with hIL-18, or neutralizes the activity of hIL-18 in vitro or in vivo. The antibody may be a total length antibody or an antigen-binding portion thereof. A method for producing the antibody and a method for using the same are also provided. The antibody or antibody portion is useful for detecting hIL-18 and for inhibiting the activity of hIL-18, for example, in a human testee suffering from a disease wherein the activity of the hIL-18 is harmful.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:The titled remedy, containing a cyclohexanecarboxylic acid derivative as an active constituent, and having the anticomplementary action, inhibitory action on blood platelet agglutination, anti-inflammatory action, inhibitory action on cellular immunity, etc. with low toxicity. CONSTITUTION:A preventing agent and remedy for renal diseases, containing a cyclohexanecarboxylic acid derivative of formulaI(A is 1-4C lower alkyl, 1- 4C lower alkoxyl, halogen, nitro, hydroxyl group, carboxyl, phenyl or pyridyl; R is alkyl; R&lt;1&gt; is H or methyl) as an active constituent. An oral agent, e.g. a tablet or capsule, a parenteral agent, e.g. an injection or suppository, may be cited as the dosage form, and the amount of the active constituent in the unit dosage form is preferably 25-2,000mg. The active constituent of formulaIis prepared by reacting a reactive derivative of a cyclohexanecarboxylic acid derivative of formula II with a compound of formula III.
1,194,902. Hair preparations. YARDLEY &amp; CO. Ltd. 23 Feb., 1967 [23 Feb., 1966], No. 53913/69. Divided out of 1,194,901. Heading A5B. [Also in Division C3] Polyarmide resins derived from a polycarboxylic acid and an alkylene polyamine are modified by reaction with a substantially equal quantity by weight of a cosmetically acceptable organic acid, ester or amide at 300 Œ .11‹C for 1 to 2.5 hours in an inert atmosphere are used in hair grooming compositions which may also contain a cosmetically acceptable oil, scent and/or colouring matter. Preferred polyamides have molecular weights of 2000 to 15000. Preferred modifying agents are castor oil, liquid lanolin, fatty acids and alkanoamides. In examples proprietary polyamides derived from polymeric fat acids are reacted with liquid lanolin or castor oil and the products are blended at lower temperatures with further liquid lanolin or castor oil (8:92 or 25:75 by weight) to form hair grooming gels.
A composition for detecting blood includes 3,3&#39;, 5, 5&#39;-tetramethylbenzidine, cumene hydroperoxide, and a surfactant. The composition is an aqueous solution. The surfactant is an anionic surfactant or a non-ionic surfactant. The composition is useful for the detection of blood, in particular occult blood in saliva. Also described are methods for detecting blood using the composition, a kit including the composition, and the use of a surfactant to reduce the time taken to detect blood. A composition for detecting blood includes 3,3&#39;, 5, 5&#39;-tetramethylbenzidine, cumene hydroperoxide, and a surfactant. The composition is an aqueous solution. The surfactant is an anionic surfactant or a non-ionic surfactant. The composition is useful for the detection of blood, in particular occult blood in saliva. Also described are methods for detecting blood using the composition, a kit including the composition, and the use of a surfactant to reduce the time taken to detect blood. A photo-curable adhesive composition for display panel assembly comprising a) at least one polyurethane acrylate having Tg value from-70 to 20â; b) at least one (meth) acrylate monomer; c) at least one chain transfer agent; d) at least two thixotropy agents, wherein first thixotropy agent is selected from the group consisting of hydrophobic fumed silica, hydrophilic fumed silica and mixtures thereof and second thixotropy agent is selected from the group consisting of modified urea, polyhydroxycarboxylic acid esters and mixtures thereof; e) at least one photoinitiator; f) at least one plasticizer; and g) at least one defoamer. The photo-curable adhesive composition can be used in bonding two transparent substrates together or in bonding one transparent substrate and one opaque substrate together. Furthermore, the composition can be used in a process of making an optical assembly.
224,891. Squibb &amp; Sons, E. R., (Assignees of Nitardy, F. W.). Nov. 13, 1923, [Convention date]. Dentifrices.-A material for use in dentifrices consists of magnesium hydroxide substantially free from water and suspended in glycerine, in which condition it is incapable of reacting with other ingredients in the dentifrice. The material is prepared by making a suspension of magnesium hydroxide in water, and draining off the water as far as possible. The product, which contains about 86 per cent of water, is placed in an evaporating pan and glycerine to the amount of water contained therein is added. The water is then removed by evaporation, which may be carried out in vacuo. The resulting product is a thick paste containing about 14 per cent of magnesium hydroxide, and may be mixed with other ingredients, e.g. precipitated chalk, glycerine, flavours, and antiseptics, to produce a dentifrice.
Described herein is a device, for insertion into a lumen of a human, the device comprising at least one cannabinoid. Optionally, the device is configured for insertion into a uterus of a female patient. The device is configured to gradually release the cannabinoid to the device&#39;s surroundings over time. Additionally, described herein are methods for treatment of a disease comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a cannabinoid via an intrauterine route. Optionally, the disease is endometrial cancer, uterine sarcoma, cervical cancer, Abnormal Pap Smears, Abnormal Uterine Bleeding, Endometriosis, Fibroids, Menopause, Ovarian Masses, Pelvic Pain, Polycystic Ovarian Syndrome, Sexually Transmitted Disease, Urinary Tract Infections, Vaginitis or ovarian cancer. Optionally, the disease is Lynch syndrome.
The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 10&lt;SUP&gt;8&lt;/SUP&gt; and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.